<h3>TipRanks 黑色星期五促销</h3>
<ul>
<li>领取 TipRanks Premium 60% 的折扣，获取您投资所需的数据驱动洞察和研究工具。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
<p>Alterity Therapeutics (AU:ATH) 发布了公告。</p>
<p>Alterity Therapeutics Limited 宣布任命 David Stamler 为董事，自 2025 年 11 月 21 日生效。此任命伴随对 Stamler 在公司证券中的利益的详细披露，包括大量已全额支付的普通股和各种期权。此举可能会影响公司的治理，并可能影响其战略方向，反映公司持续致力于加强其领导团队。</p>
<p><strong>关于 Alterity Therapeutics 的更多信息</strong></p>
<p>Alterity Therapeutics Limited 在生物技术行业运营，专注于开发神经退行性疾病的治疗方案。该公司致力于创造创新治疗，以满足该领域未满足的医疗需求。</p>
<p><strong>平均交易量：</strong> 14,994,693</p>
<p><strong>技术情绪信号：</strong> 强烈卖出</p>
<p><strong>当前市值：</strong> 9788 万澳元</p>
<p>在 TipRanks 的股票分析页面上找到 ATH 股票的详细分析。</p>

ATHE

<p>Alterity Therapeutics 已任命 David Stamler 为董事，任命自 2025 年 11 月 21 日生效，并披露了他的证券权益，包括股票和期权。此次任命可能会影响公司的治理和战略方向，突显其加强领导层的承诺。Alterity Therapeutics 专注于开发神经退行性疾病的治疗方案</p>

<h3>TipRanks Black Friday Sale</h3>
<div class="lb-trans"><h3>TipRanks 黑色星期五促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>领取 TipRanks Premium 60% 的折扣，获取您投资所需的数据驱动洞察和研究工具。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
</div><p>Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.</p>
<div class="lb-trans"><p>Alterity Therapeutics (AU:ATH) 发布了公告。</p>
</div><p>Alterity Therapeutics Limited has announced the appointment of David Stamler as a director, effective November 21, 2025. This appointment is accompanied by a detailed disclosure of Stamler’s interests in the company’s securities, which include a significant number of fully paid ordinary shares and various options. This move is likely to impact the company’s governance and could influence its strategic direction, reflecting the company’s ongoing commitment to strengthening its leadership team.</p>
<div class="lb-trans"><p>Alterity Therapeutics Limited 宣布任命 David Stamler 为董事，自 2025 年 11 月 21 日生效。此任命伴随对 Stamler 在公司证券中的利益的详细披露，包括大量已全额支付的普通股和各种期权。此举可能会影响公司的治理，并可能影响其战略方向，反映公司持续致力于加强其领导团队。</p>
</div><p><strong>More about Alterity Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Alterity Therapeutics 的更多信息</strong></p>
</div><p>Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company is dedicated to creating innovative treatments to address unmet medical needs in this sector.</p>
<div class="lb-trans"><p>Alterity Therapeutics Limited 在生物技术行业运营，专注于开发神经退行性疾病的治疗方案。该公司致力于创造创新治疗，以满足该领域未满足的医疗需求。</p>
</div><p><strong>Average Trading Volume:</strong> 14,994,693</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 14,994,693</p>
</div><p><strong>Technical Sentiment Signal:</strong> Strong Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 强烈卖出</p>
</div><p><strong>Current Market Cap:</strong> A$97.88M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 9788 万澳元</p>
</div><p>Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析页面上找到 ATH 股票的详细分析。</p>
</div>

Alterity Therapeutics 宣布新董事的任命及其证券权益